Hepion Pharmaceuticals adds two new directors
Hepion Pharmaceuticals, Inc. reported that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026.
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. reported that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026. This expands the company’s board and adds new oversight at the corporate level.
The filing notes there are no arrangements or understandings with other persons related to their selection, and no family relationships among the new directors and other company figures, except that Gary S. Stetz, II is the son of Interim Chief Executive Officer Gary Stetz.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board appointment effective date: July 1, 2026
Par value of common stock: $0.0001 per share
Trading symbol: HEPA
3 metrics
Board appointment effective date
July 1, 2026
Effective date for appointments of Danina Fisher and Gary S. Stetz, II as directors
Par value of common stock
$0.0001 per share
Par value of Hepion Pharmaceuticals common stock registered under Section 12(b)
Trading symbol
HEPA
Ticker symbol for Hepion Pharmaceuticals common stock on the OTC market
Key Terms
Emerging growth company, Board of Directors, principal executive offices, Section 12(b) of the Act
4 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Board of Directors financial
"the Board of Directors of Hepion Pharmaceuticals, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
principal executive offices regulatory
"(Address of principal executive offices)"
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change to Hepion Pharmaceuticals (HEPA) leadership was disclosed?
Hepion Pharmaceuticals disclosed that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026. This expands board membership and updates the company’s governance structure with two additional members.
Who are the new directors joining Hepion Pharmaceuticals (HEPA)?
The new directors are Danina Fisher and Gary S. Stetz, II. They were approved by the Board of Directors and their appointments became effective immediately on July 1, 2026, according to the company’s current report.
Are there any family relationships involving Hepion’s new directors?
Yes. The filing states there is no family relationship among the new directors and others at the company, except that Gary S. Stetz, II is the son of Interim Chief Executive Officer Gary Stetz, creating a disclosed familial link at the leadership level.
Were any special arrangements involved in selecting Hepion’s new directors?
The company states there are no arrangements or understandings between Danina Fisher or Gary S. Stetz, II and any other person pursuant to which they were selected as directors. Their appointments were approved by the Board without disclosed side agreements.
What is Hepion Pharmaceuticals’ trading symbol and market?
Hepion Pharmaceuticals’ common stock trades under the symbol HEPA on the OTC market. The filing identifies the security as common stock with a par value of $0.0001 per share registered under Section 12(b) of the Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
